NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to ...

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively targets classical pathway while preserving lectin ...

Dianthus Therapeutics, Inc. is headquartered in New York City. The company is focused on developing complement therapeutics for patients with severe autoimmune and inflammatory diseases.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of ...

Follow our easy guide to taking cuttings and you can create a summer display of your favourite variety of dianthus. A cottage garden favourite, pinks are easy to grow and look good at the front of ...